TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors

Clinical trial NCT04969315 · RECRUITING

Trial details

NCT number: NCT04969315
Sponsor: Portage Biotech
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Renal Cell Cancer Castrate Resistant Prostate Cancer Non Small Cell Lung Cancer Head and Neck Squamous Cell Carcinoma Colorectal Cancer (CRC)Endometrial Cancer Ovarian Cancer

Start date: 2023-06-23
Primary completion: 2026-06-01
Enrollment: 90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.